Sarepta Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Sarepta Therapeutics's estimated annual revenue is currently $645.6M per year.(i)
  • Sarepta Therapeutics received $375.0M in venture funding in November 2017.
  • Sarepta Therapeutics's estimated revenue per employee is $594,986
  • Sarepta Therapeutics's total funding is $1.4B.
  • Sarepta Therapeutics's current valuation is $6.2B. (January 2022}

Employee Data

  • Sarepta Therapeutics has 1085 Employees.(i)
  • Sarepta Therapeutics grew their employee count by -3% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare diseases. Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in Limb-girdle muscular dystrophy (LGMD), Charcot-Marie-Tooth (CMT) and CNS-related disorders, reaching a total of over 20 therapies in various stages of development. The Company's programs span across several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is poised to be the most meaningful precision genetic medicine company in the world and make a profound difference in the lives of patients suffering from rare neuromuscular diseases and other rare diseases. For more information, please visit



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Sarepta Therapeutics News

2016-03-22 - FDA urged to approve Sarepta DMD drug by dozens of medical experts

More than three dozen medical experts are urging the Food and Drug Administration to approve a Sarepta Therapeutics medicine for combating Duchenne muscular dystrophy, a rare disease that causes muscles in boys to stop working and eventually results in death because they can no longer breathe. ...

2021-08-27 - Sarepta Therapeutics : Measurements Used in Clinical Trials for Duchenne Muscular Dystrophy – an Overview

Sarepta is working hard to develop precision genetic medicines for patients with rare diseases who often have limited or no treatment options, including Duchenne. Clinical trials are critical for understanding the safety and effectiveness of our investigational medicines. The results of these st ...

2021-11-03 - Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Recent Corporate Developments

Net product sales for the third quarter of 2021 reached $166.9 million, a 37% increase over the same quarter of prior yearIn light of its continued over-performance, Sarepta raises its full-year product revenue guidance by $40 million to between $605 million to $615 million CAMBRIDGE, Mass., No ...

09/03/2019 - Here's Why Sarepta Therapeutics Dropped 39.4% in August

Shares of Sarepta Therapeutics (NASDAQ: SRPT) fell more than 39% last month, according to data provided by S&P Global Market Intelligence ...

09/08/2019 - Charles Schwab Investment Management Inc. Grows Stock Holdings in Sarepta Therapeutics Inc (NASDAQ:SRPT)

Charles Schwab Investment Management Inc. grew its holdings in shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) by 8.9% in the 2nd ...

09/03/2019 - Sarepta Therapeutics, Inc. (SRPT): Average 1-Day Percentage Change on Earnings

32 days have passed by since the last earnings report for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and the new quarterly results look set to ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Sarepta Therapeutics Funding

DateAmountRoundLead InvestorsReference
2002-03-27$22.0MPrivate Equity FinaArticle
2003-05-06$15.0MPrivate PlacementArticle
2003-12-05$15.0MEquity PlacementArticle
2005-11-15$22.6MUndisclosedRodman and Renshaw LLCArticle
2009-02-04$16.5MUndisclosedEastbourne Capital ManagementArticle
2009-08-21$30.0MUndisclosedJefferies & Company IncArticle
2011-04-04$30.0MUndisclosedLazard Capital Markets LLC, Piper Jaffray & CoArticle
2015-06-30$40.0MUndisclosedMidcap FinancialArticle
2015-10-07$127.0MUndisclosedCredit SuisseArticle
2016-06-10$37.5MUndisclosedCredit SuisseArticle
2016-09-23$225.0MUndisclosedJ.P. MorganArticle
2016-09-26$300.0MUndisclosedJ.P. MorganArticle
2017-07-25$287.5MUndisclosedGoldman Sachs & Co. LLCArticle